Phase 3 win lifts $ROIV — shares gap & pop after brepocitinib data ➤ +6.53% intraday, 2.54% gap; ~7% from 52W high ➤ Short ratio 6.15, short float 9.04% — squeeze potential ➤ Avg vol 6.35M; 457 funds with +6.5% position growth #ROIV #biotech #Phase3 🧬Q